千红制药（002550）：QHRD107EHA数据点评：Ⅱa期初步数据优秀，临床进展顺利

Investment Rating - The investment rating for Qianhong Pharmaceutical is "Buy" (maintained) [1][10] Core Views - QHRD107, a CDK9 inhibitor, shows significant clinical progress with preliminary data from the EHA 2025 conference, indicating a substantial improvement in overall survival (OS) for patients with relapsed/refractory acute myeloid leukemia (R/R AML) [3][9] - The reported data includes 51 patients, with an overall response rate (ORR) of 60.9% and a complete clinical response (cCR) of 41.3%. In the subgroup of relapsed patients, the ORR is 70.0% and cCR is 45.0% [3] - The median OS for patients who are refractory/relapsed after VEN-AZA treatment reached 12.8 months, demonstrating the effectiveness of QHRD107 in addressing unmet clinical needs in the R/R AML field [3][9] Financial Forecasts - The projected total revenue for Qianhong Pharmaceutical is expected to be 1,814 million RMB in 2023, decreasing to 1,526 million RMB in 2024, and then increasing to 2,051 million RMB in 2025, 2,737 million RMB in 2026, and 3,283 million RMB in 2027 [1][10] - The net profit attributable to the parent company is forecasted to be 181.86 million RMB in 2023, increasing to 356.03 million RMB in 2024, and further to 443.10 million RMB in 2025, 511.97 million RMB in 2026, and 609.02 million RMB in 2027 [1][10] - The earnings per share (EPS) is projected to rise from 0.14 RMB in 2023 to 0.48 RMB in 2027, with a corresponding price-to-earnings (P/E) ratio decreasing from 61.65 to 18.41 over the same period [1][10]